Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 2/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NT5E | P21589 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10220755 | 0.82 | TSHR (0.33) | KDM4ELMNA | |
| SCHEMBL4371685 | 0.77 | NT5E (0.39) | KDM4EPDE2APDE10ANT5E | |
| SCHEMBL1584056 | 0.77 | NOS3 (0.44) | KDM4ECXCR4PDE2APDE10ALMNA | |
| SCHEMBL31018185 | 0.76 | TRPV4 (0.45) | KDM4ECXCR4PDE2APDE10ALMNA | |
| SCHEMBL21612748 | 0.76 | TRPV4 (0.45) | KDM4ECXCR4PDE2APDE10ALMNA | |
| SCHEMBL21139679 | 0.76 | KDM4E (0.42) | KDM4ECXCR4LMNAGAA | |
| Ammonia Solution, Strong SCHEMBL27852366 | 0.76 | NOS3 (0.43) | KDM4ECXCR4PDE2APDE10ALMNA | |
| SCHEMBL15832406 | 0.76 | LMNA (0.46) | KDM4ECXCR4PDE2APDE10ALMNA | |
| SCHEMBL2634744 | 0.76 | NOTUM (0.42) | KDM4EPDE2APDE10ANT5E | |
| SCHEMBL15284060 | 0.76 | NT5E (0.38) | KDM4EPDE2APDE10ANT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111902419-B | Novel nucleosides or nucleotide derivatives and use thereof | ST制药株式会社 | 2023-11-24 | — | — | CN | disclosed |
| WO-2023114200-A2 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF | ALEXION PHARMACEUTICALS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023114198-A2 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20230022157-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-11345714-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20210139500-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. (US) | 2021-05-13 | — | — | US | disclosed |
| US-10870638-B2 | Pyridazinone compound or its salt, and herbicide containing it | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2020-12-22 | — | — | US | disclosed |
| US-20200172517-A1 | PYRIDAZINONE COMPOUND OR ITS SALT, AND HERBICIDE CONTAINING IT | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2020-06-04 | — | — | US | disclosed |
| US-10336771-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180170948-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | Bio TheryX, Inc. | 2018-06-21 | — | — | US | disclosed |
| EP-1957461-B1 | BISAMIDE INHIBITORS OF HEDGEHOG SIGNALING | GENENTECH INC (US) | 2016-11-02 | — | — | EP | disclosed |
| US-8101610-B2 | Blocking signals; anticancer agents | GENENTECH, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-7528151-B2 | Heterocyclic urea derivatives for the treatment of pain | GLAXO GROUP LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| US-7528151-B2 | Heterocyclic urea derivatives for the treatment of pain | GLAXO GROUP LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| US-20080269215-A1 | Bisamide Inhibitors of Hedgehog Signaling | GENENTECH INC. (US) | 2008-10-30 | — | — | US | disclosed |
| EP-1957461-A1 | BISAMIDE INHIBITORS OF HEDGEHOG SIGNALING | Genentech, Inc. (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007059157-A1 | BISAMIDE INHIBITORS OF HEDGEHOG SIGNALING | GENENTECH, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070117820-A1 | Heterocyclic urea derivatives for the treatment of pain | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-24 | — | — | US | disclosed |
| US-20070117820-A1 | Heterocyclic urea derivatives for the treatment of pain | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117820-A1 | Heterocyclic urea derivatives for the treatment of pain | U2SURP, UMPS, SFPQ | KDM4E 2326/4885CXCR4 1133/4885PDE2A 263/4885 |
| US-11345714-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | CKS1B, IKZF3, EPAS1 | KDM4E 4006/4885CXCR4 1083/4885PDE2A 3493/4885 |
| US-20210139500-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | CKS1B, IKZF3, CKS2 | KDM4E 4043/4885CXCR4 1093/4885PDE2A 3491/4885 |
| US-20180170948-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | CKS1B, IKZF3, EPAS1 | KDM4E 4006/4885CXCR4 1083/4885PDE2A 3493/4885 |
| US-10870638-B2 | Pyridazinone compound or its salt, and herbicide containing it | H1-0, H1-4, H1-3 | KDM4E 1092/4885CXCR4 2344/4885PDE2A 2947/4885 |
| US-10336771-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | CKS1B, IKZF3, EPAS1 | KDM4E 4006/4885CXCR4 1083/4885PDE2A 3493/4885 |
| US-20230022157-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | CFD, CFH, TFPI | KDM4E 4475/4885CXCR4 2659/4885PDE2A 2788/4885 |
| US-20200172517-A1 | PYRIDAZINONE COMPOUND OR ITS SALT, AND HERBICIDE CONTAINING IT | H1-0, H1-4, H1-3 | KDM4E 1092/4885CXCR4 2344/4885PDE2A 2947/4885 |
| US-20080269215-A1 | Bisamide Inhibitors of Hedgehog Signaling | SHH, GLI1, SMO | KDM4E 710/4885CXCR4 2839/4885PDE2A 2721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.